Travere TherapeuticsTVTX
Recorded

Travere Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration28 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Dejia ZhangInvestment Banking Coverage Team

Hello. All right. Thank you, everyone, for coming today. My name is Dejia Zhang, and I am on the UBS Investment Banking Coverage Team. I am so excited to have all of you here and attend our inaugural conference this year in London. I am also really excited to announce Chris Cline as the Chief Financial Officer of Travere Therapeutics.

Chris ClineCFO

Well, thank you, Deja, and thank you, UBS, for having us. It is great to be here with you all, and I am very excited to spend some time talking about Travere Therapeutics. I will be making forward-looking statements, so please see our 10-K and 10-Q for full risk factors and forward-looking disclosures. When we think about Travere Therapeutics, we are exclusively focused on delivering life-changing therapies for people living with rare disease. We do that in a host of different ways. The first is in the commercial side, where we have a full commercial organization that is delivering multiple approved medicines, FILSPARI for IgA nephropathy, as well as FSGS, two rare progressive kidney diseases, and Thiola EC and Thiola, which are our legacy businesses that are targeting cystinuria, basically the standard of care for another rare kidney disease.

Chris ClineCFO

We have seen very excellent execution and growth in the recent years in the commercial side of the business, but we also have a pipeline that has two programs that have best-in-class potential, one for a disease called classical homocystinuria, or HCU, and this is pegtibatinase, it is an enzyme replacement therapy that is currently in phase III. Also civorebrutinib, or sibo, and this is our most recent addition to the pipeline. This is a next-generation BTK inhibitor that we are going to be moving forward in multiple immune-mediated kidney diseases. In order to continue our trajectory of performance and growth in the recent history and to really turn that into durable long-term growth, we are focusing on four key strategic pillars. These pillars, the first two of which are focused on FILSPARI, and FILSPARI has had significant growth both in IgA and more recently in FSGS.

Chris ClineCFO

What we want to make sure we are doing is focusing our efforts on continuing that momentum and continuing to maintain that foundational placement that has been built. The first growth driver is in IgA nephropathy, and we have been approved here since February of 2023. FILSPARI is the only nephroprotective medicine that can replace the historical standard of care, and that is exactly what our commercial organization has been doing in reaching patients. The goal of the priority number one is to continue to maintain that momentum as we see the IgA nephropathy space continue to expand and the treatment paradigm evolve. The second growth driver is tied to the recent approval in FSGS for FILSPARI. In April of this past year, we got approved for focal segmental glomerulosclerosis, or FSGS, and here what we have seen is a very strong start to the commercial launch.

Chris ClineCFO

We're only two quarters in, but we're seeing broad adoption and very strong response from the nephrology community for having the first and only approved medicine for FSGS, and importantly, that's for both adults and pediatric patients. The second priority here really is focused on continuing that early adoption and getting to that foundational positioning in FSGS as well. The third and the fourth priorities are really tied towards the next wave of growth that we expect to have alongside and beyond FILSPARI. These are tied to the pipeline, and the third priority being focused on pegtibatinase. As I mentioned before, this is our enzyme replacement therapy that's targeting classical homocystinuria, and if approved, it would be the first and only disease-modifying therapy for classical HCU.

Chris ClineCFO

We're currently enrolling a phase III study called the HARMONY Study that we expect to be able to support a BLA submission. Our current focus there is to ensure that we get to full enrollment so that we can have a data readout in the second half of next year, and we're firmly on track to do that. The last priority that you see here is on civorebrutinib. This again, this is the latest addition to our pipeline. Here, the main goal is to begin development as what we look at as a potential pipeline and a product. For civorebrutinib, we've been licensed this from Everest Medicines, and so we're in the process of opening up an IND in the U.S.

Chris ClineCFO

Our goal here is to submit and have that cleared so that we can begin our dosing work to do bridging, as well as some optimization before we go and engage with FDA to establish our global regulatory plans for multiple late-stage studies and immune-mediated kidney diseases. So very exciting time and very clear focus on these key growth drivers that we expect to drive value both in the near term and then also as we move forward into the next decade. Let me start first with FILSPARI and really focus in on IgA nephropathy and FSGS. When you think about FILSPARI, we have an overall opportunity to reach more than 100,000 patients with these two diseases. IgA nephropathy is believed to have about 70,000 addressable patients, and FSGS is more than 30,000.

Chris ClineCFO

We expect that both of these diseases are going to see increased biopsy, increased diagnosis, and earlier treatment as physicians continue to adapt to new treatment guidelines, but then also as we see more and more treatments becoming available, greater education and awareness. So a very large and expanding market opportunity as a whole for FILSPARI. FILSPARI is very uniquely placed. It is a once-a-day oral medication. It is the only non-immunosuppressive medicine that has been trialed against the historical standard of care and can actively replace or upgrade what patients have historically used as their foundational care. So, very clear differentiated profile that will enable it to continue to be used. What we see is that with its profile of once daily oral and having a generally safe and well-tolerated profile, that patients are highly compliant and persistent on therapy when they begin.

Chris ClineCFO

If a patient starts therapy, they typically will stay on for extended periods of time. We have a very strong commercial platform to leverage. When you think about the call points for nephrology, we call on about 7,000 nephrologists, and there's a very high overlap between those that are seeing IgA nephropathy patients and FSGS patients, more than 80%. We've got a built-in expertise, established relationships, and years of experience to be able to continue meeting the needs of the physicians and reaching patients. When you think about that overall and put it together, we look at this as an opportunity of potentially more than $1 billion or $3 billion in net sales potential by the year 2033. We've talked historically about IgA nephropathy being larger than $1 billion potentially, and FSGS being even larger than that.

Chris ClineCFO

Everything that we see so far in our trajectory in both markets continues to support that. I'll talk a little bit about that now, where we look at our third quarter results. In the third quarter, we saw U.S. net product sales of FILSPARI increase about 120% over the same period last year to eclipsing $200 million. This was really driven by a host of different factors. First, for those patients that have already been prescribed FILSPARI, in IgAN especially, you see strong persistence and compliance, as I mentioned before. That's a growing base of revenue that we're seeing being contributed from IgA nephropathy.

Chris ClineCFO

We're also seeing in the second quarter of launch now for FSGS, this is the first time that we're seeing a contribution from the revenues in that indication, which has been encouraging to see how quickly we've been able to both see strong conversion, but then also from a payer access standpoint, all of the work that's gone to date with payers is translating into early adoption and reimbursement. On the demand side, we saw 1,932 new patient start forms, which is incredibly strong and especially encouraging given typically in the third quarter, we see summer seasonality. That's driven across the market by fewer physicians, or by fewer patients seeing their physicians and people taking vacation. This is something that we've seen in years past. There's typically a slight lowering in demand.

Chris ClineCFO

We were very encouraged to see the continued strong uptake of FILSPARI both in IgA and FSGS. We're seeing this happen, importantly, with both new and repeat prescribers. In IgA nephropathy, even though we're a number of years into the launch, we're still identifying new prescribers, and you're seeing continued deepening within practices. In FSGS, we're also seeing both new and repeat prescribers. Interestingly, with FSGS, what we commented on is that roughly two-thirds of physicians have only written a prescription to one patient within their practice. We know that in many of the practices, or most of the practices, they're going to have a handful or more patients. We know that they are just in the early days of adoption. Very encouraging from a demand perspective. I'll talk a little bit about each of the individual indications.

Chris ClineCFO

Starting first with IgA nephropathy, you are talking about a very progressive disease where high-risk patients typically will advance to kidney failure within around 11 years. Unfortunately, this is happening at the peak of life for these patients. You are talking about individuals who are in their mid-20s to late 30s, and oftentimes they will go to transplant or dialysis, and oftentimes transplant will fail due to recurrence. So a devastating disease hitting people at the prime of their life. There are more than 70,000 patients that we believe are out there, and we are still early in being able to reach the overall population. I will talk a minute about the current KDIGO guidelines. We saw a shift here in 2025 when the KDIGO guidelines were updated. It used to be believed that for IgA nephropathy, if a patient was around 1 gram of proteinuria, they were largely stabilized.

Chris ClineCFO

But data over time has shown us that the treatment goal really should be 0.5 or preferably complete remission, 0.3 grams of proteinuria. The new KDIGO guidelines reflected that adjustment in terms of more ambitious treatment targets. They also included FILSPARI as being the foundational care, and also to potentially use it ahead of RAS inhibition. The KDIGO guidelines have also now suggested that you really should be looking to biopsy patients with any sign of proteinuria and aiming to treat earlier. So that is driving a nice shift within the nephrology space for nephrologists to really seek out their patients, seek treatment earlier, and to drive to the lowest proteinuria they possibly can get, because proteinuria is the only validated biomarker to help make those decisions on a regular basis. Also within the KDIGO guidelines is this evolving treatment paradigm, which shows two aspects of the disease.

Chris ClineCFO

For nephrologists, they think about having to treat both the overactivation in the kidney, and this is where FILSPARI plays a key role, as well as the overactivation in the immune system. There is no single medicine that addresses both of these aspects of the disease, and really what we are seeing happen is an upgrade, if you will, of historical standards of care on both different sides, and them being used in combination. Starting on the kidney side, what has historically been used as the standard of care has been RAS inhibition and SGLT2, and now we are seeing that FILSPARI is becoming foundation and being that first choice to switch from the RAS inhibition, and even use ahead of RAS inhibition, to address the overactivation specifically in the kidney, and the nephroprotective properties of FILSPARI really lend well to that adoption.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day